Show simple item record

dc.contributor.authorTurner, Suzanneen
dc.contributor.authorLamant, Laurenceen
dc.contributor.authorKenner, Lukasen
dc.contributor.authorBrugières, Laurenceen
dc.date.accessioned2016-01-07T17:25:44Z
dc.date.available2016-01-07T17:25:44Z
dc.date.issued2016-02-23en
dc.identifier.citationTurner et al. British Journal of Haematology (2016). doi: 10.1111/bjh.13958en
dc.identifier.issn0007-1048
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/253156
dc.description.abstractAnaplastic large cell lymphoma (ALCL) is a heterogeneous disease of debateable origin, which in children is largely anaplastic lymphoma kinase (ALK) positive with aberrant ALK activity induced following the formation of chromosomal translocations. Whilst the survival rates for this disease are relatively high, a large proportion of patients suffer disease relapse, in some cases on multiple occasions and therefore suffer the toxic side-effects of combination chemotherapy. Traditionally, patients are treated with a combination of agents although recent data from relapse patients have suggested that low risk patients might benefit from single agent vinblastine and going forward the addition of ALK inhibitors to the therapeutic regimen may have beneficial consequences. There are also a plethora of other drugs that might be advantageous to patients with ALCL and many of these have been identified through laboratory research although the decision as to which drugs to implement in trials will not be trivial.
dc.description.sponsorshipSupported in part by the Pediatric Cancer Research Foundation and Fondazione Giacomo Ascoli. S.D.T. is supported with funding from Bloodwise
dc.languageEnglishen
dc.language.isoenen
dc.publisherWiley
dc.subjectanaplastic large cell lymphomaen
dc.subjectanaplastic lymphoma kinaseen
dc.subjectT cell lymphomaen
dc.subjectALK inhibitorsen
dc.titleAnaplastic large cell lymphoma in paediatric and young adult patientsen
dc.typeArticle
dc.description.versionThis is the author accepted manuscript. The final version is available from Elsevier via http://dx.doi.org/10.1111/bjh.13958en
prism.publicationDate2016en
prism.publicationNameBritish Journal of Haematologyen
rioxxterms.versionofrecord10.1111/bjh.13958en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2016-02-23en
dc.contributor.orcidTurner, Suzanne [0000-0002-8439-4507]
dc.identifier.eissn1365-2141
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idLeukaemia & Lymphoma Research (12065)
pubs.funder-project-idIsaac Newton Trust (1439(K))
pubs.funder-project-idChildren with Cancer UK (16-209)
rioxxterms.freetoread.startdate2017-02-23


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record